News

atai and bionomics

Atai Life Sciences Partners with Bionomics on MDMA Combination Therapies

Bionomics (BNO), an Australian listed clinical stage biopharmaceutical company announced on Wednesday that it has partnered with EmpathBio, a subsidiary of the largest private psychedelic company, ATAI Life Sciences. Through the new partnership, the companies will explore a combination drug treatment regimen using EmpathBio’s MDMA derivative, EMP-01, and Bionomics’ lead drug candidate, BNC210.  The regimen […]

Tryp Therapeutics IPO

Tryp Therapeutics Goes Public; Here’s Everything You Need to Know

Tryp Therapeutics, a development-stage pharmaceutical company focused on psilocybin and other treatments, will begin trading on the Canadian Stock Exchange (CSE) today under the symbol “TRYP”. After initially attempting to sell 17.4 million units at $0.25 to investors, the company said Monday it would fully exercise its over-allotment option, increasing the total number of units […]